Atai: Following the path that Spravato laid and moving beyond it

Srinivas Rao, CEO of Atai Life Sciences, leads a biotech revolution in mental health through psychedelic compounds. He discusses the promising use of MDMA for social anxiety and the influence of Johnson & Johnson's Spravato on market potential. Rao highlights groundbreaking clinical trials, including their innovative BPL-03 formulation. He also addresses the need for effective treatments in cognitive impairment linked to schizophrenia and the evolving regulatory landscape, emphasizing optimism for the future of psychedelic medicine.